[1]
|
Rastogi, A., Ameen, K.M., Al-Baghdadi, M., et al. (2019) Autosomal Dominant Polycystic Kidney Disease: Updated Perspectives. Therapeutics and Clinical Risk Management, 15, 1041-1052. https://doi.org/10.2147/TCRM.S196244
|
[2]
|
Willey, C.J., Blais, J.D., Hall, A.K., et al. (2017) Prevalence of Au-tosomal Dominant Polycystic Kidney Disease in the European Union. Nephrology Dialysis Transplantation, 32, 1356-1363.
|
[3]
|
Xue, C., Zhou, C.C., Wu, M., et al. (2016) The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. Kidney Disease (Basel), 2, 111-119. https://doi.org/10.1159/000449030
|
[4]
|
Torres, V.E. and Harris, P.C. (2019) Progress in the Understanding of Polycystic Kidney Disease. Nature Reviews Nephrology, 15, 70-72. https://doi.org/10.1038/s41581-018-0108-1
|
[5]
|
Chebib, F.T. and Torres, V.E. (2018) Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrolo-gy, 13, 1765-1776.
https://doi.org/10.2215/CJN.03960318
|
[6]
|
Perumareddi, P. and Trelka, D.P. (2020) Autosomal Dominant Poly-cystic Kidney Disease. Primary Care, 47, 673-689.
https://doi.org/10.1016/j.pop.2020.08.010
|
[7]
|
Chapman, A.B., Devuyst, O., Eckardt, K.U., et al. (2015) Autoso-mal-Dominant Polycystic Kidney Disease (ADPKD): Executive Summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 88, 17-27. https://doi.org/10.1038/ki.2015.59
|
[8]
|
Jagtap, J.M., Gregory, A.V., Homes, H.L., et al. (2022) Automated Meas-urement of Total Kidney Volume from 3D Ultrasound Images of Patients Affected by Polycystic Kidney Disease and Comparison to MR Measurements. Abdominal Radiology (NY), 47, 2408-2419. https://doi.org/10.1007/s00261-022-03521-5
|
[9]
|
常染色体显性多囊肾病临床实践指南专家委员会, 薛澄, 李林, 梅长林. 中国常染色体显性多囊肾病临床实践指南(第二版) [J]. 临床肾脏病杂志, 2019, 19(4): 227-235.
|
[10]
|
Pei, Y., Obaji, J., Dupuis, A., et al. (2009) Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology, 20, 205-212. https://doi.org/10.1681/ASN.2008050507
|
[11]
|
Lanktree, M.B., Haghighi, A., di Bari, I., et al. (2021) Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies. Clinical Journal of the American Society of Nephrology, 16, 790-799.
https://doi.org/10.2215/CJN.02320220
|
[12]
|
Chebib, F.T., Perrone, R.D., Chapman, A.B., et al. (2018) A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal of the American Society of Nephrology, 29, 2458-2470.
https://doi.org/10.1681/ASN.2018060590
|
[13]
|
Shimoda, N., Ikeda, M., Yan, T., et al. (2022) Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. Journal of Nippon Medi-cal School, 89, 287-294.
https://doi.org/10.1272/jnms.JNMS.2022_89-303
|
[14]
|
Bellos, I. (2021) Safety Profile of Tolvaptan in the Treat-ment of Autosomal Dominant Polycystic Kidney Disease. Therapeutics and Clinical Risk Management, 17, 649-656. https://doi.org/10.2147/TCRM.S286952
|
[15]
|
Hogan, M.C., Chamberlin, J.A., Vaughan, L.E., et al. (2020) Pan-somatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Clinical Journal of the American Society of Neph-rology, 15, 1267-1278.
https://doi.org/10.2215/CJN.13661119
|
[16]
|
Holditch, S.J., Brown, C.N., Atwood, D.J., et al. (2019) A Study of Sirolimus and mTOR Kinase Inhibitor in a Hypomorphic Pkd1 Mouse Model of Autosomal Dominant Polycystic Kidney Disease. American Journal of Physiology-Renal Physiology, 317, F187-F196. https://doi.org/10.1152/ajprenal.00051.2019
|
[17]
|
Ruggenenti, P., Gentile, G., Perico, N., et al. (2016) Effect of Si-rolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology, 11, 785-794. https://doi.org/10.2215/CJN.09900915
|
[18]
|
Tesar, V., Ciechanowski, K., Pei, Y., et al. (2017) Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology, 28, 3404-3413. https://doi.org/10.1681/ASN.2016111232
|
[19]
|
Casarella, A., Nicotera, R., Zicarelli, M.T., et al. (2022) Autosomic Dominant Polycystic Kidney Disease and Metformin: Old Knowledge and New Insights on Retarding Pro-gression of Chronic Kidney Disease. Medicinal Research Reviews, 42, 629-640. https://doi.org/10.1002/med.21850
|
[20]
|
Kramers, B.J., Koorevaar, I.W., van Gastel, M.D.A., et al. (2022) Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial. Clinical Journal of the American Society of Nephrology, 17, 507-517. https://doi.org/10.2215/CJN.11260821
|
[21]
|
Bais, T., Gansevoort, R.T. and Meijer, E. (2022) Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. Drugs, 82, 1095-1115. https://doi.org/10.1007/s40265-022-01745-9
|
[22]
|
Li, A., Tian, X., Zhang, X., et al. (2015) Human Polycystin-2 Transgene Dose-Dependently Rescues ADPKD Phenotypes in Pkd2 Mutant Mice. The American Journal of Pathology, 185, 2843-2860.
https://doi.org/10.1016/j.ajpath.2015.06.014
|
[23]
|
Li, W., Ma, Y., Yu, S., et al. (2017) The Mutation-Free Embryo for in Vitro Fertilization Selected by MALBAC-PGD Resulted in a Healthy Live Birth from a Family Carrying PKD 1 Mutation. Journal of Assisted Reproduction and Genetics, 34, 1653-1658. https://doi.org/10.1007/s10815-017-1018-z
|
[24]
|
熊晖, 相玉柱, 齐太国, 金讯波. 常染色体显性多囊肾病不同时期行腹腔镜去顶减压术后疗效分析[J]. 中国医刊, 2017, 52(11): 41-43.
|
[25]
|
El Chediak, A., Degheili, J.A. and Khauli, R.B. (2021) Genitourinary Interventions in Autosomal Dominant Polycystic Kidney Disease: Clinical Recom-mendations for Urologic and Transplant Surgeons. Experimental and Clinical Transplantation, 19, 95-103. https://doi.org/10.6002/ect.2020.0292
|
[26]
|
郭晶晶, 年莉. 中医药治疗多囊肾研究进展[J]. 临床合理用药杂志, 2018, 11(10): 175-177.
|
[27]
|
陈燕钦, 张喜奎. 张喜奎教授治疗多囊肾经验拾萃[J]. 福建中医药, 2019, 50(5): 57-58.
|
[28]
|
林文秋, 王子燕, 包崑, 侯海晶, 杨霓芝. 杨霓芝教授治疗常染色体显性遗传型多囊肾的临证经验[J]. 中国中西医结合肾病杂志, 2020, 21(10): 847-849.
|
[29]
|
戴润, 黄一珊, 张帅星, 李春, 刘玉宁. 刘玉宁教授治疗多囊肾的临床经验[J]. 中国中西医结合肾病杂志, 2018, 19(10): 850-851.
|
[30]
|
张小鹿, 王振华, 郁胜强, 王怡. 259例常染色体显性遗传型多囊肾病患者中医证型分析[J]. 中国中医药信息杂志, 2012, 19(12): 16-19.
|
[31]
|
郭晶. 结合数据挖掘的多囊肾中医诊疗规律研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2020.
|
[32]
|
景艺雅. 中药三棱肾区离子导入治疗多囊肾的临床观察[C]//中国中西医结合学会肾脏疾病专业委员会2018年学术年会论文摘要汇编. 2018: 1725.
|
[33]
|
徐成钢, 梅长林, 赵海丹. 土鳖虫水煎剂对人多囊肾病囊肿衬里上皮细胞增殖的影响[J]. 第二军医大学学报, 2002(2): 200-202.
|
[34]
|
杨焕荣, 杨淑美, 王广鑫, 等. 雷公藤内酯醇对多囊肾囊肿衬里上皮细胞增殖和凋亡的影响[J]. 医药导报, 2016, 35(9): 920-924.
|